Effect of antihypertensive therapy on plasma catecholamines in renal failure patients

W. L. Henrich, H. Mitchell, S. Anderson, R. Cronin, W. A. Pettinger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The influence of antihypertensive therapy on plasma norepinephrine (NE) was examined in 58 patients with moderate chronic renal failure (CRF). Six normotensive patients not receiving antihypertensive medicines (mean serum creatinine 2.4 ± .2 mg/dl) had a modest but significant increase in NE compared to normals in both supine (230 vs. 173 pg/ml, P<.05) and upright (482 vs. 377 pg/ml, P<.05) positions. A striking increase in NE (supine 673 ± 55, P<.001; upright 1089 ± 88 pg/ml, P<.001) was observed in 34 CRF patients receiving antihypertensive regimens containing diuretic, β-blocker, or vasodilator drugs either individually or in combination. Vasodilator therapy was associated with the highest levels of NE. In 17 further CRF patients receiving the sympathetic suppressants clonidine or methyldopa in addition to the other medicines, NE values were similar to untreated, normotensive patients (supine NE 254 ± 40 pg/ml; upright NE 474 ± 61 pg/ml). The age, degree of renal impairment, plasma renin activity, and number of dosage of antihypertensive medicines did not account for these differences in NE. The results suggest that NE levels are modestly increased in normotensive, untreated CRF patients, but are dramatically increased by antihypertensive therapy, particularly vasodilator therapy. Clonidine or methyldopa therapy, however, is associated with significantly lower NE values in these patients despite the concomitant use of vasodilator agents.

Original languageEnglish (US)
Pages (from-to)131-136
Number of pages6
JournalClinical Nephrology
Volume16
Issue number3
StatePublished - 1981

Fingerprint

Antihypertensive Agents
Catecholamines
Renal Insufficiency
Norepinephrine
Vasodilator Agents
Chronic Kidney Failure
Therapeutics
Methyldopa
Clonidine
Diuretics
Renin
Creatinine
Kidney
Serum

ASJC Scopus subject areas

  • Nephrology

Cite this

Henrich, W. L., Mitchell, H., Anderson, S., Cronin, R., & Pettinger, W. A. (1981). Effect of antihypertensive therapy on plasma catecholamines in renal failure patients. Clinical Nephrology, 16(3), 131-136.

Effect of antihypertensive therapy on plasma catecholamines in renal failure patients. / Henrich, W. L.; Mitchell, H.; Anderson, S.; Cronin, R.; Pettinger, W. A.

In: Clinical Nephrology, Vol. 16, No. 3, 1981, p. 131-136.

Research output: Contribution to journalArticle

Henrich, WL, Mitchell, H, Anderson, S, Cronin, R & Pettinger, WA 1981, 'Effect of antihypertensive therapy on plasma catecholamines in renal failure patients', Clinical Nephrology, vol. 16, no. 3, pp. 131-136.
Henrich WL, Mitchell H, Anderson S, Cronin R, Pettinger WA. Effect of antihypertensive therapy on plasma catecholamines in renal failure patients. Clinical Nephrology. 1981;16(3):131-136.
Henrich, W. L. ; Mitchell, H. ; Anderson, S. ; Cronin, R. ; Pettinger, W. A. / Effect of antihypertensive therapy on plasma catecholamines in renal failure patients. In: Clinical Nephrology. 1981 ; Vol. 16, No. 3. pp. 131-136.
@article{263fbc01fb1b48a0978232ce87fdce8a,
title = "Effect of antihypertensive therapy on plasma catecholamines in renal failure patients",
abstract = "The influence of antihypertensive therapy on plasma norepinephrine (NE) was examined in 58 patients with moderate chronic renal failure (CRF). Six normotensive patients not receiving antihypertensive medicines (mean serum creatinine 2.4 ± .2 mg/dl) had a modest but significant increase in NE compared to normals in both supine (230 vs. 173 pg/ml, P<.05) and upright (482 vs. 377 pg/ml, P<.05) positions. A striking increase in NE (supine 673 ± 55, P<.001; upright 1089 ± 88 pg/ml, P<.001) was observed in 34 CRF patients receiving antihypertensive regimens containing diuretic, β-blocker, or vasodilator drugs either individually or in combination. Vasodilator therapy was associated with the highest levels of NE. In 17 further CRF patients receiving the sympathetic suppressants clonidine or methyldopa in addition to the other medicines, NE values were similar to untreated, normotensive patients (supine NE 254 ± 40 pg/ml; upright NE 474 ± 61 pg/ml). The age, degree of renal impairment, plasma renin activity, and number of dosage of antihypertensive medicines did not account for these differences in NE. The results suggest that NE levels are modestly increased in normotensive, untreated CRF patients, but are dramatically increased by antihypertensive therapy, particularly vasodilator therapy. Clonidine or methyldopa therapy, however, is associated with significantly lower NE values in these patients despite the concomitant use of vasodilator agents.",
author = "Henrich, {W. L.} and H. Mitchell and S. Anderson and R. Cronin and Pettinger, {W. A.}",
year = "1981",
language = "English (US)",
volume = "16",
pages = "131--136",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "3",

}

TY - JOUR

T1 - Effect of antihypertensive therapy on plasma catecholamines in renal failure patients

AU - Henrich, W. L.

AU - Mitchell, H.

AU - Anderson, S.

AU - Cronin, R.

AU - Pettinger, W. A.

PY - 1981

Y1 - 1981

N2 - The influence of antihypertensive therapy on plasma norepinephrine (NE) was examined in 58 patients with moderate chronic renal failure (CRF). Six normotensive patients not receiving antihypertensive medicines (mean serum creatinine 2.4 ± .2 mg/dl) had a modest but significant increase in NE compared to normals in both supine (230 vs. 173 pg/ml, P<.05) and upright (482 vs. 377 pg/ml, P<.05) positions. A striking increase in NE (supine 673 ± 55, P<.001; upright 1089 ± 88 pg/ml, P<.001) was observed in 34 CRF patients receiving antihypertensive regimens containing diuretic, β-blocker, or vasodilator drugs either individually or in combination. Vasodilator therapy was associated with the highest levels of NE. In 17 further CRF patients receiving the sympathetic suppressants clonidine or methyldopa in addition to the other medicines, NE values were similar to untreated, normotensive patients (supine NE 254 ± 40 pg/ml; upright NE 474 ± 61 pg/ml). The age, degree of renal impairment, plasma renin activity, and number of dosage of antihypertensive medicines did not account for these differences in NE. The results suggest that NE levels are modestly increased in normotensive, untreated CRF patients, but are dramatically increased by antihypertensive therapy, particularly vasodilator therapy. Clonidine or methyldopa therapy, however, is associated with significantly lower NE values in these patients despite the concomitant use of vasodilator agents.

AB - The influence of antihypertensive therapy on plasma norepinephrine (NE) was examined in 58 patients with moderate chronic renal failure (CRF). Six normotensive patients not receiving antihypertensive medicines (mean serum creatinine 2.4 ± .2 mg/dl) had a modest but significant increase in NE compared to normals in both supine (230 vs. 173 pg/ml, P<.05) and upright (482 vs. 377 pg/ml, P<.05) positions. A striking increase in NE (supine 673 ± 55, P<.001; upright 1089 ± 88 pg/ml, P<.001) was observed in 34 CRF patients receiving antihypertensive regimens containing diuretic, β-blocker, or vasodilator drugs either individually or in combination. Vasodilator therapy was associated with the highest levels of NE. In 17 further CRF patients receiving the sympathetic suppressants clonidine or methyldopa in addition to the other medicines, NE values were similar to untreated, normotensive patients (supine NE 254 ± 40 pg/ml; upright NE 474 ± 61 pg/ml). The age, degree of renal impairment, plasma renin activity, and number of dosage of antihypertensive medicines did not account for these differences in NE. The results suggest that NE levels are modestly increased in normotensive, untreated CRF patients, but are dramatically increased by antihypertensive therapy, particularly vasodilator therapy. Clonidine or methyldopa therapy, however, is associated with significantly lower NE values in these patients despite the concomitant use of vasodilator agents.

UR - http://www.scopus.com/inward/record.url?scp=0019489591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019489591&partnerID=8YFLogxK

M3 - Article

C2 - 7296970

AN - SCOPUS:0019489591

VL - 16

SP - 131

EP - 136

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 3

ER -